In 2014, nearly 60% of Americans had at least one chronic condition, and 42% had more than one indicating a rising trend in chronic inflammatory diseases
A lot of the generics conversation is actually coming from us as health-care providers to say, hey, we know that this isn't an option for you right now because of cost but it will likely be an option for you very soon because of the generics and the hopefulness around reduction in cost, Poddar said
PubMed Drucker DJ (2018)
Crockett Chair in Diabetes Research, medical director of AdventHealth Diabetes Institute and a Healio | Endocrine Today Co-editor, described the FLOW findings as practice changing. Pratley said while the American Diabetes Association Standards of Care recommends SGLT2 inhibitors as the first-line treatment for most adults with type 2 diabetes and CKD, the FLOW trial may change that in the future
While many people tolerate GLP-1s well, theres always a chance that youll experience issues, and you want a direct line to a knowledgeable healthcare provider just in case
